State Street Corp Fulcrum Therapeutics, Inc. Transaction History

State Street Corp

$2.59 Trillion
Q2 2025

A detailed history of State Street Corp transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, State Street Corp holds 1,218,366 shares of FULC stock, worth $7.97 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,218,366

Previous 1,252,440 2.72%

Holding current value

$7.97 Million

Previous $3.61 Million 132.38%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$2.51 - $7.38 $85,525 - $251,466	-34,074 Reduced 2.72%	1,218,366 $8.38 Million
Q1 2025 May 15, 2025	BUY	$2.88 - $5.08 $20,508 - $36,174	7,121 Added 0.57%	1,252,440 $3.61 Million
Q4 2024 Feb 14, 2025	SELL	$2.97 - $4.84 $1.29 Million - $2.1 Million	-434,910 Reduced 25.88%	1,245,319 $5.85 Million
Q3 2024 Nov 14, 2024	BUY	$3.18 - $9.74 $2.03 Million - $6.22 Million	638,955 Added 61.36%	1,680,229 $6 Million
Q2 2024 Aug 14, 2024	BUY	$5.98 - $9.31 $4.69 Million - $7.3 Million	784,413 Added 305.38%	1,041,274 $6.46 Million
Q1 2024 May 15, 2024	BUY	$6.7 - $12.0 $493,883 - $884,568	73,714 Added 40.25%	256,861 $2.42 Million
Q3 2023 Nov 14, 2023	SELL	$3.25 - $6.08 $74,100 - $138,624	-22,800 Reduced 11.07%	183,147 $813,000
Q2 2023 Aug 14, 2023	SELL	$2.26 - $3.8 $1.72 Million - $2.89 Million	-759,641 Reduced 78.67%	205,947 $679,000
Q1 2023 May 15, 2023	BUY	$2.83 - $13.99 $524,042 - $2.59 Million	185,174 Added 23.73%	965,588 $2.75 Million
Q4 2022 Feb 14, 2023	BUY	$5.01 - $8.35 $275,033 - $458,389	54,897 Added 7.57%	780,414 $5.68 Million
Q3 2022 Nov 15, 2022	BUY	$4.92 - $9.1 $378,106 - $699,344	76,851 Added 11.85%	725,517 $5.87 Million
Q2 2022 Aug 15, 2022	SELL	$4.2 - $24.0 $114,609 - $654,912	-27,288 Reduced 4.04%	648,666 $3.18 Million
Q1 2022 May 16, 2022	SELL	$9.96 - $23.65 $218,691 - $519,283	-21,957 Reduced 3.15%	675,954 $16 Million
Q4 2021 Feb 14, 2022	BUY	$14.0 - $28.44 $3.44 Million - $6.98 Million	245,599 Added 54.3%	697,911 $12.3 Million
Q3 2021 Nov 15, 2021	BUY	$7.28 - $30.97 $1.02 Million - $4.34 Million	140,087 Added 44.87%	452,312 $12.8 Million
Q2 2021 Aug 16, 2021	BUY	$8.09 - $12.0 $467,019 - $692,736	57,728 Added 22.68%	312,225 $3.27 Million
Q1 2021 May 17, 2021	BUY	$10.94 - $15.32 $164,625 - $230,535	15,048 Added 6.28%	254,497 $3 Million
Q4 2020 Feb 16, 2021	BUY	$7.84 - $13.4 $214,768 - $367,079	27,394 Added 12.92%	239,449 $2.8 Million
Q3 2020 Nov 10, 2020	BUY	$7.22 - $20.7 $35,789 - $102,609	4,957 Added 2.39%	212,055 $1.68 Million
Q2 2020 Aug 14, 2020	BUY	$9.11 - $22.06 $116,935 - $283,162	12,836 Added 6.61%	207,098 $3.79 Million
Q1 2020 May 11, 2020	BUY	$9.49 - $21.26 $1.84 Million - $4.13 Million	194,262 New	194,262 $2.32 Million

Others Institutions Holding FULC

# of Institutions

130

Shares Held

55.5M

Call Options Held

886K

Put Options Held

93.3K

View Full List

About Fulcrum Therapeutics, Inc.

Ticker FULC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,038,900
Market Cap $340M
Description
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...

More about FULC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account

State Street Corp Fulcrum Therapeutics, Inc. Transaction History